Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can result in death. Global cancer prevalence rates are on the rise owing to an aging population and changing lifestyle, lung cancer is one of the most common types of cancer, with an estimated 1.2 million new cases being diagnosed every year.
The global market for cancer drugs has hit $100 billion in annual sales, and could reach $147 billion by 2018, according to a new report by the IMS. Blood cancer drugs market was the highest revenue generating segment in 2013 due to its high cost of drugs used for the treatment of blood cancer.
Growth in the drugs market will be seen in emerging and developing markets like India, China, Brazil and Indonesia at about 24% as being predicted by IMS. China will lead the charge with $160 billion to $190 billion in spending by 2020. Meanwhile, cheap drugs will fuel spending, too, as volume grows worldwide. The cost per month for a new cancer drug has increased 40%, or $5,900, over the past decade.
North America, dominates the drug market followed by Europe. North America accounted for about ~38% share in the overall oncology drugs market in 2013.
On the other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the same period and would emerge as the most attractive market by 2020.
US spends the most on cancer drugs as an absolute amount.
The geographic distribution of sales in the cancer market includes the US and the EU featuring prominently among the leading global cancer markets.
Oncology drug spending has risen slightly as a percentage of total drug spending over the past five years in all regions, most notably in the EU5(France, Germany, Italy, Spain, United Kingdom) countries where oncology now represents
14.7% of total drug spending, up from 13.3% in 2010. In the U.S., oncology has increased more modestly from 10.7% to 11.3% of total drug spending over the same period. The biggest increase on a percentage basis was in the U.K.; the lowest was in Spain.
Global Cancer Drugs Market Dynamics
- Rising availability and prevalence of various cancer types.
- Advancement of anti-cancer drugs research
- Growing importance of biological and targeted drug therapies.
The Cancer Drug Market has been bifurcated by the following cancer types:
- Lung Cancer: Overall, lung cancer is one of the most common types of cancer. The epidemic of this disease has been seen both in developed and developing countries with high mortality rates.
There are two main types of lung cancer; small cell lung cancer that accounts for about 20% and non-small cell lung cancer (NSCLC) that accounts for about 80% of the total lung cancers.
The lung cancer drugs market was valued at around $4 billion in 2010 and is expected to reach about $13 billion by 2020, growing at a CAGR of 13.5% from 2015 to 2020.
The U.S. dominates the lung cancer drug market in North America with 93.5% (total sales of lung cancer drugs) share; whereas Germany dominates the market of Europe with 32.4% share.
- Breast Cancer: Breast cancer is the most common cancer in women and has the largest market in terms of numbers of patients diagnosed.
Globally, breast cancer is the most common type of cancer, accounting for 10% of all cancer types.
There are several factors that increase the development of breast cancer – most likely being age or family history of breast cancer. It is estimated that in 2012 over 1.5 million people were affected by breast cancer.
Sales of breast cancer treatments are set to increase by an average of 5.8% a year in major markets, increasing from a value of $9.8 billion in 2013 to $18.2 billion by 2023, according to IMS Health.
According to IMS study, nine countries- US, France, Germany, Italy, Spain, UK, Japan, China and Brazil-1.2 million patients received drug treatment in 2013, and the number is predicted to reach about 1.4 million patients in 2023.
The market size for the five EU countries is set to increase from $3.3 billion in 2013 to $5.1 billion by 2023 (3.9% CAGR).
The global market for breast cancer diagnostic and drug technologies was about $20.8 billion in 2012. This market reached about $22.3 billion in 2014 and is expected to reach $27 billion in 2019, registering a compound annual growth rate (CAGR) of 4% through 2014-2019.
- Leukaemia (blood cancer): Leukaemia is a cancer of the blood or bone marrow involving abnormal proliferation of blood cells mostly white blood cells (WBCs, or leukocytes). All leukaemia arises from mutations or damage to the DNA within the blood cells.
The prevalence leukaemia in the seven major markets is expected to grow from 2,24,060 in 2010 to 2, 31,210 in 2016.
The US was the leading market with an estimated drug sales value of $1.8 billion in 2011 and an approximate share of 44.3%. The US market is expected to grow at a CAGR of 10.0% between 2011 and 2018 to record sales value of $3.5 billion in 2018.
The top five countries of Europe (France, Germany, Italy, Spain, United Kingdom) together contributed to sales worth $1.5 billion in 2011, accounting for share of 37.9%. The top five countries of Europe are expected to record sales worth $3.1 billion by the year 2018, at a CAGR of 10.3%.
Japan, in 2011, contributed $720m to the global market increasing at a CAGR of 20.8% from 2004. It accounts for an approximate share of 17.8%. Growing at a CAGR of 6.1% between 2011 and 2018, the market is expected to record sales worth $1.1 billion by 2018.
The leukemia therapeutics market was valued at $6.3 billion in 2010 and is expected to reach $11.3 billion by 2020.
- Pancreatic Cancer: Pancreatic cancer is a malignant tumour that develops in the pancreatic tissues inside the small digestive organ, the pancreas.
Pancreatic cancer is most common in people from age group of 60-75, thus making age the predominant factor of this disease; other factors can be smoking, alcohol consumption and obesity, a personal or family history of pancreatitis.
The incidence and mortality rate of pancreatic cancer is higher in men than in women, SEER estimates that there were 46,420 new pancreatic cancer cases recorded in the US in 2014.
The global pancreatic cancer market is experiencing rapid expansion and is set to hit $1.6bn by 2017.
The US will show the most growth in the pancreatic cancer therapeutics market, with its total value expanding from $275 million in 2012 to $1.17 billion by 2017, at a higher CAGR of 33.5%.
The US will be followed by the five European countries, with their combined market values expected to increase from $254 million in 2012 to $463 million by 2017, at a CAGR of 12.8% thus a combined valuation climbing from $529m in 2012 to $1.63bn by 2017.
- Prostate Cancer: Prostate cancer is a malignant tumour, or group of cancerous cells, which arises in the prostate gland, a gland in the male reproductive system located below the urinary bladder and in front of the rectum.
It is third most common cancer affecting men, representing 10% of all cases.
Prostate cancer generally occurs in men over the age of 50- most common factors being hereditary mutations, diets that have too much red meat content and environmental factors affecting the male hormones (androgen).
The prostate cancer market, in the 9MM (the US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) is forecasted to rapidly increase from $2.6bn in 2013 to $8.3bn in 2023, at a CAGR of 12.4%.
Prostate cancer ranks sixth in terms of cancer-related mortality rate in men.
- Ovarian Cancer: Ovarian cancer is a malignant tumour affecting the ovaries. It is the second most common type of gynaecological malignancy in the world- most common factors being Hormonal, environmental and genetic factors also play important roles in the development of ovarian cancer.
This cancer can be further bifurcated into four categories:
- Ovarian epithelial carcinoma- accounts for more than 80% of ovarian cancers.
- Germ cell tumor- constitutes 5% of all ovarian cancers and mostly among young women and girls.
- Sex cord stromal ovarian carcinoma- accounts for about 8% of ovarian cancers.
- Rare ovarian tumors that are largely benign in nature- account for an estimated 1% of ovarian cancer cases.
The prevalence of ovarian cancer is set to grow from 170,280 in 2010 to 174,429 in 2016. In 2012 alone, the number of new cases of ovarian cancer stood at 239,000, constituting 1.7% of all cancer cases worldwide, according to World Cancer Research Fund International.
North American dominates the global market due to increasing ageing population. Asia is expected to show high growth rates in the next five years in the global ovarian cancer market. China and India are expected to be the fastest growing ovarian cancer markets in Asia-Pacific region.
The Ovarian drug market saw an indispensable revenue increasing from $460 million in 2011 and expected to reach $1.4 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan, due to the emergence of new drugs and therapies.
The other cancers which constitute the global cancer drug market are head and neck cancer, colorectal cancer, etc.
- Existing cancer treatments are increasingly improving patient outcomes.
- New drugs and combination of drugs along with therapeutic research are emerging with promise of more rapid and better patient benefits.
- Oncology pipelines have produced 45 new drugs launched in 2010-14 for more than 53 uses.
- Survival rates have steadily improved over the past 20 years.
The entire pharmaceutical industry is bringing on 3D printing technology for the manufacturing of drug. This technology will increase the efficiency of experimentation of the drug for the treatment of diseases.